



Bioject Inc. develops and markets Needle-Free Injection Therapy (N FIT) systems for the Pharmaceutical, and Biotech industries. The company is focused on establishing strategic partnerships and expanding mutually beneficial agreements to provide unique injection systems that enhance the delivery of its partner's injected medications or vaccines.

The U.S. injectable market is forecasted to grow significantly due to new pharmaceutical, biotechnology and vaccine developments. Annual sales of injectable products are forecasted to reach \$49 billion by 2014\*. Product differentiation has become increasingly important and needle-free delivery will continue to be a viable solution.

- Bioject is a leading company with over 20 years of experience.

Over 20 million human injections have been given using Bioject's systems  
 Award-winning and unique products  
 ISO 13485 certified  
 Eleven cleared 510(K)s  
 Extensive patent portfolio

- Bioject has both spring and gas-powered needle-free systems for intramuscular, subcutaneous and intradermal delivery.
- Bioject has a range of products allowing it to deliver volumes from 0.05 mL to 1.0 mL. In addition, the company has various new devices under development including an intradermal pen and a pre-filled single-use disposable option.

### Bioject Inc.

7180 SW Sandburg St., Ste. 100 Tigard, OR 97223 USA

503-692-8001 [www.bioject.com](http://www.bioject.com)

Customer Service: 800-683-7221 ext. 4122

[customerservice@bioject.com](mailto:customerservice@bioject.com)